UnitedHealth Group Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Comparisons are with Q1 2023 unless stated otherwise. UnitedHealth Group operates UnitedHealthcare and Optum, with four reportable segments: UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. Amounts are in U.S. dollars.
Financial performance
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Total revenue | $99.8 billion | $91.9 billion |
| Earnings from operations | $7.9 billion | $8.1 billion |
| Net earnings attributable to common shareholders | $(1.4) billion | $5.6 billion |
| Diluted earnings per share | $(1.53) | $5.95 |
| Cash flow from operations | $1.1 billion | $16.3 billion |
| Medical care ratio | 84.3% | 82.2% |
| Operating cost ratio | 14.1% | 14.8% |
| Consolidated operating margin | 7.9% | 8.8% |
Revenue increased 9%. Premiums rose 7%, products 16%, and services 10%. Medical costs increased 10%, faster than premiums, while operating costs increased 3%. The company reported $1.2 billion of income tax benefit; the tax rate was not meaningful because of the Brazil sale loss.
Segment results: UnitedHealthcare revenue rose 7% to $75.4 billion and operating earnings increased 1% to $4.4 billion. Optum revenue rose 13% to $61.1 billion, while operating earnings fell 6% to $3.5 billion. Optum Health revenue increased 16% and operating earnings 7%; Optum Insight revenue was nearly flat, with operating earnings down 46%; Optum Rx revenue increased 12% and operating earnings 8%.
Financial position and liquidity
- At March 31, 2024, cash and cash equivalents were $28.4 billion, total assets $284.2 billion, and total liabilities $187.3 billion.
- Short-term borrowings and current maturities of long-term debt were $9.8 billion; long-term debt was $63.9 billion. The company issued $6.0 billion of senior notes in March and had $7.3 billion of commercial paper outstanding at a weighted-average annual rate of 5.4%.
- Operating cash flow fell to $1.1 billion from $16.3 billion. Management cited the prior-year receipt of an $11.2 billion CMS premium payment in March 2023, cyberattack-related provider support and payment timing, and public-sector cash receipt timing.
- Financing cash flow included $6.2 billion net proceeds from short-term borrowings, $5.9 billion of long-term debt issuance, $3.1 billion of share repurchases and $1.7 billion of dividends. The quarterly dividend represented an annual rate of $7.52 per share.
- Management stated that capital resources were sufficient for short- and long-term liquidity needs. Only $2.1 billion of the $28.4 billion cash balance was available for general corporate use, according to the filing. The defined debt-to-debt-plus-shareholders’ equity ratio was approximately 43%, against a credit-facility limit of 60%.
Material changes and unusual items
- Change Healthcare cyberattack: Identified February 21, 2024. The company incurred $593 million of direct response costs in Q1, including $340 million of medical costs related to temporarily suspended care-management activities, and estimated $279 million of Optum Insight business disruption impact. It provided approximately $3.9 billion in accelerated funding and interest-free loans to providers through March 31; that amount exceeded $6.5 billion through April 30. Management expected further response costs and disruption during the year.
- The company reported that initial data sampling found files containing protected health information or personally identifiable information that could cover a substantial proportion of people in America; the investigation was ongoing. Management warned of potential litigation, reputational and regulatory risks, and possible adverse financial effects.
- Brazil operations sale: Completed February 6, 2024, producing a $7.1 billion loss, including $4.1 billion of accumulated foreign currency translation losses reclassified from accumulated other comprehensive loss. The loss was not deductible for income tax purposes and drove the reported net loss.
- The medical care ratio rose 2.1 percentage points. Management attributed the increase to Medicare funding reductions, cyberattack-related provider accommodations and less favorable reserve development. The company also reported increased outpatient procedures among seniors and said care-management activities resumed early in Q2.
- Domestic UnitedHealthcare membership increased by 1.6 million year over year, while Medicaid membership declined 700,000 amid redeterminations. Medicare Advantage membership rose 215,000. Global commercial membership fell, partly reflecting the Brazil disposition.
- Available-for-sale debt securities had $2.9 billion of gross unrealized losses, which the company attributed primarily to interest rates; it said it did not intend to sell securities in unrealized-loss positions and expected to collect principal and interest.
Outlook, risks and contingencies
The filing provides no specific numerical earnings or revenue guidance. Management described ongoing Medicare Advantage funding pressure: 2024 and 2025 rate notices were below forward medical cost trends, and risk-adjustment model changes were expected to reduce funding. Potential responses include cost management, provider-network and benefit changes, member premiums, and decisions on where to offer plans. Management also cited medical-cost estimation and pricing, cyber and data-security events, government program and regulatory changes, litigation and investigations, and capital-market access among risks that could cause results to differ materially from expectations.
Pending acquisitions subject to customary conditions and regulatory approval had anticipated consideration of approximately $4 billion, excluding acquired debt. The company disclosed ongoing legal and governmental matters, including a DOJ False Claims Act case concerning Medicare risk-adjustment submissions; it said the outcome could not reasonably be estimated. CMS risk-adjustment data validation audits may result in retrospective payment adjustments. No material changes to the risk factors in the 2023 Form 10-K were reported.
Important facts for investors to verify
- How the cyberattack’s restoration costs, lost business, provider support, data exposure and any related claims or regulatory actions develop after quarter-end.
- Whether medical-cost trends, reserve development and Medicare Advantage funding changes affect the medical care ratio and segment margins in subsequent quarters.
- The cash-flow impact of provider loans, public-sector receipt timing and the unusually large prior-year CMS payment comparison.
- The final financial, legal and tax effects of the Brazil disposition and the completion and integration of pending acquisitions.
- Debt, commercial paper, general-purpose cash availability and compliance with credit-facility covenants as capital needs evolve.